During a Case-Based Roundtable® event, Lori J. Wirth, discussed the SELECT trial and the role of multikinase inhibitors in ...
Lenvatinib plus pembrolizumab has improved survival rates for patients with intermediate-stage hepatocellular cancer, ...
Finally, the assay can be used with Merck’s Keytruda (pembrolizumab) and GSK’s Jemperli (dostarlimab) across solid tumors ...
MedPage Today on MSN1d
Upfront TKI for Bone-Predominant RCC Tops Single-Agent ImmunotherapyMedian overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a ...
Pharmac has decided to fund lenvatinib from 1 December 2024 for people with some types of thyroid, liver, and kidney cancer. Lenvatinib (branded as Lenvima) stops the number of cancer cells from ...
People with some types of thyroid and liver cancer are getting free access to a targeted treatment for the first time, with ...
According to data from the phase 3 double-blinded, active-controlled, multicenter LEAP-012 trial (NCT04246177), lenvatinib (Lenvima) with pembrolizumab (Keytruda) and transarterial chemoembolization ...
as well as in a combination regimen alongside Eisai's Lenvima (lenvatinib) in previously treated endometrial cancer without dMMR mutations. Approval in first-line endometrial cancer would be a ...
The list including Bristol-Myers Squibb’s cancer immunotherapy Opdivo (nivolumab), Eli Lilly’s Cyramza (ramucirumab), Eisai’s Lenvima (lenvatinib), Bayer’s Stivarga (regorafenib) ...
MI Cancer Seek has received approval from the FDA as a companion diagnostic test to identify those who may benefit from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback